Drug Spending Information Products Fact Sheet
- Date
- 2018-05-15
- Title
- Drug Spending Information Products Fact Sheet
- Contact
- press@cms.hhs.gov
Drug Spending Information Products Fact Sheet
Today, the Centers for Medicare & Medicaid Services (CMS) announced the release of updated information products that provide greater transparency on drug spending in the Medicare and Medicaid programs. CMS is releasing updated versions of the Drug Spending Dashboards and the annual update to the Part D Prescriber Public Use File. These tools and resources, which provide data through 2016, focus on giving consumers, researchers, and other stakeholders across the healthcare system the information they need to understand drug prescribing in CMS programs, with a particular focus on spending.
CMS Drug Spending Dashboards
CMS is releasing new and improved versions of the Drug Spending Dashboards with data through 2016. These dashboards are interactive, online tools that allow consumers, researchers, policy-makers, and other stakeholders to understand changes in spending on prescription drugs in the Medicare and Medicaid programs. With this release of the dashboards, CMS is highlighting year-over-year changes in per unit spending for individual drugs at both the drug and the manufacturer-level. CMS is also expanding the dashboards to include the majority of drugs prescribed under these programs. This data is critical to providing transparency around prescription drug price increases.
The dashboards include information for Medicare Part B, Medicare Part D, and Medicaid. The tools focus on average spending per dosage unit and change in average spending per dosage unit over time. They also display consumer-friendly information on drug uses and clinical indications as well as spending information on manufacturer(s) of the drugs, where available. [1] The dashboards do not contain any patient-identifiable data. The dashboards and a downloadable, machine-readable version of the data presented in the dashboards can be accessed at: https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Information-on-Prescription-Drugs/index.html .
Medicare Part B Drug Spending Dashboard
The Medicare Part B Drug Spending Dashboard (Part B Dashboard) presents spending information for Medicare Part B drugs, which are generally administered in doctors’ offices and other outpatient settings. Part B drug spending and utilization information is available for Medicare fee-for-service beneficiaries enrolled in Part B, but excludes any beneficiaries enrolled in Medicare Advantage (which represents approximately 30% of the Medicare population).
Figure 1 presents information pulled from the Medicare Part B Dashboard on select drugs with annual increases in spending per dosage unit from 2012 to 2016 of more than 5%. This list is derived from the 15 drugs with the highest total spending in Medicare Part B in 2016. In 2016, total spending these 8 drugs was over $6.7 billion.
Figure 1: High Annual Increases in Spending, Medicare Part B
Medicare Part B
Brand Name
Generic Name
Annual Growth Rate (2012-2016)
Average Monthly Spending Per Beneficiary in 2016
Manufacturers
1
Orencia*
Abatacept*
17.2%($22 to $41)
$2,136
BMS Primarycare
2
Neulasta
Pegfilgrastim
8.5%($2,788 to $3,869)
$1,195
Amgen
3
Xolair
Omalizumab
8.0%($22 to $30)
$1,821
Genentech, Inc.
4
Vaccine Influenza Injection Muscle (Fluzone High-Dose)**
6.9%($30 to $39)
N/A
5
Sandostatin Lar*
Octreotide Acetate, mi-Spheres*
6.8%($123 to $160)
$3,202
Novartis
6
Prevnar 13
Pneumococcal 13-Valent Vaccine
6.1%($132 to $167)
N/A
Wyeth Pharm
7
Remicade
Infliximab
6.0%($63 to $80)
$1,910
Janssen Biotech
8
Rituxan
Rituximab
5.6%($615 to $765)
$1,985
Genentech, Inc.
*Indicates multiple brand and/or generic names for a specific HCPCS code.**Indicates brand/generic names unavailable. Name reflects the HCPCS short description.
Medicare Part D Drug Spending Dashboard
The Medicare Part D Drug Spending Dashboard (Part D Dashboard) presents spending information for Medicare Part D drugs, which are generally administered by patients. Part D drug spending and utilization information is available from the Part D Prescription Drug Event (PDE) data. These data are available for the subset of Medicare beneficiaries who choose to enroll in Part D (which represents approximately 70% of Medicare beneficiaries).
Figure 2 presents information pulled from the Medicare Part D Dashboard on select drugs with annual increases in spending per dosage unit from 2012 to 2016 of more than 10%. This list is derived from the 15 drugs with the highest total spending in Medicare Part D in 2016. In 2016, total spending for these 13 drugs was over $26 billion.
Figure 2: High Annual Increases in Spending, Medicare Part D
Medicare Part D
Brand Name
Generic Name
Annual Growth Rate (2012-2016)
Average Monthly Spending Per Beneficiary in 2016
Manufacturers
1
Renvela
Sevelamer Carbonate
21.6%($3 to $6)
$630
Genzyme
2
Lantus
Insulin Glargine, Hum.Rec.Anlog
18.6%($13 to $25)
$209
Sanofi-Aventis
3
Zetia
Ezetimibe
18.3%($5 to $9)
$181
Merck Sharp & D
4
Enbrel
Etanercept
18.2%($498 to $972)
$2,741
Amgen
5
Humira Pen
Adalimumab
18.0%($1,019 to $1,976)
$2,835
Abbvie US LLC
6
Lyrica
Pregabalin
17.4%($3 to $6)
$205
Pfizer US Pharm
7
Lantus Solostar
Insulin Glargine, Hum.Rec.Anlog
14.2%($14 to $25)
$196
Sanofi-Aventis
8
Crestor
Rosuvastatin Calcium
13.2%($5 to $8)
$124
Astrazeneca
9
Januvia
Sitagliptin Phosphate
12.7%
($7 to $12)
$235
Merck Sharp & D
10
Xarelto
Rivaroxaban
10.6%($8 to $12)
$202
Janssen Pharm.
11
Eliquis
Apixaban
10.4%($4 to $6)
$194
BMS Primarycare
Medicaid Drug Spending Dashboard & Data
The Medicaid Drug Spending Dashboard (Medicaid Dashboard) presents spending information on drugs paid through the Medicaid program. Medicaid drug data represent national-level drug utilization information for covered outpatient drugs paid for by State Medicaid agencies.
Figure 3 presents information pulled from the Medicaid Dashboard on select drugs with annual increases in spending per dosage unit from 2012 to 2016 of more than 10%. This list is derived from the 15 drugs with the highest total spending in Medicaid in 2016. In 2016, total spending for these 8 drugs was nearly $6.6 billion.
Figure 3: High Annual Increases in Spending, Medicaid
Medicaid
Brand Name
Generic Name
Annual Growth Rate (2012-2016)
Manufacturers
1
Lantus
Insulin Glargine, Hum.Rec.Anlog
18.7%($13 to $25)
Sanofi-Aventis
2
Latuda
Lurasidone HCl
18.6%($17 to $33)
Sunovion Pharma
3
Lyrica
Pregabalin
17.9%($3 to $6)
Pfizer US Pharm
4
Enbrel
Etanercept
17.6%($487 to $933)
Amgen
5
Humira Pen
Adalimumab
17.5%($1,007 to $1,919)
Abbvie US LLC
6
Lantus Solostar
Insulin Glargine, Hum.Rec.Anlog
14.3%($15 to $25)
Sanofi-Aventis
7
Abilify
Aripiprazole
11.4%($21 to $32)
Otsuka America
8
Vyvanse
Lisdexamfetamine Dimesylate
11.0%($5 to $8)
Shire US Inc.
Part D Prescriber Public Use File
CMS is also updating the Part D Prescriber Public Use File (PUF) with data for 2016. The Part D Prescriber PUF provides key information to consumers, providers, researchers, and the public to enable a wide range of analyses on the prescribing of drugs paid for under the Medicare Part D program.
The Part D Prescriber PUF includes summarized information on prescription drugs that were prescribed by individual physicians and other health care providers and paid for under the Medicare Part D Prescription Drug Program in 2016. The data include the specific medications prescribed and statistics on utilization and costs organized by the prescriber National Provider Identifier (NPI), drug name (brand name in the case of trademarked drugs) and generic name. The PUF provides data on more than one million distinct health care providers who collectively prescribed $146 billion in prescription drugs under the Part D program in 2016.
The 2016 PUF and supplemental information are available at: https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/PartD2016.html .
[1] Information on manufacturer-level spending is not available for Part B drugs since the HCPCS payment is the same across all manufacturers.
###
Get CMS news at cms.gov/newsroom
, sign up for CMS news via email
and follow CMS on Twitter CMS Administrator @SeemaCMS
, @CMSgov
, and @CMSgovPress